Vanda Pharmaceuticals Inc. announced that on March 16, 2015, Steven K. Galson, M.D., M.P.H. notified the Board of Directors of the company that he did not intend to stand for re-election at the company's 2015 Annual Meeting of Stockholders so that he may devote his full time efforts to his other commitments. The Board has appointed Richard Dugan, a current director, to succeed Dr. Galson as a member of the Nominating/Corporate Governance Committee of the Board, effective upon the expiration of Dr. Galson's term.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.940 USD | -2.76% | -0.80% | +17.06% |
12:59pm | FDA Decision Due on Vanda Pharma's Gastroparesis Drug | DJ |
07-31 | Transcript : Vanda Pharmaceuticals Inc., Q2 2024 Earnings Call, Jul 31, 2024 |
- Stock Market
- Equities
- VNDA Stock
- News Vanda Pharmaceuticals Inc.
- Vanda Pharmaceuticals Inc. Announces Nominating/Corporate Governance Committee Changes